As mentioned in Fierce Biotech, a new crop of biotech IPO hopefuls have recently thrown their hats into the ring. These three biotechs are targeting $175M in IPO cash, hoping to secure funding for oncology, pain, and rare diseases.
In fact, there have been 96 IPOs since the passage of the JOBS Act in April of 2012. One important provision of the Act is the ability for emerging growth companies to conduct “testing the waters” meetings with potential investors. Biotechs have reported that these meetings, which were not allowed before the JOBS Act passed, have been extremely helpful in generating interest in their offering.
Through the BIO catalog of events, including the 13th Annual 2014 BIO Investor Forum, companies, such as those mentioned in the Fierce article, have the opportunity to showcase their story through presentations to qualified investors. The 2014 BIO Investor Forum will assemble a select group of early- and late- stage companies, established and emerging public biotechs, and top public and private equity investors to explore investment trends and opportunities in life sciences. Since 2011, 44% of all US therapeutic IPO companies participated in a BIO Investor Forum event as a private company.
The conference features presentations by over 100 biotech companies poised to join the growth “watch list” in 2015, as well as a number of nonprofit and venture philanthropy organizations. The typical audience for all presentations features public and private equity investors, research analysts, investment bankers and industry executives.
A handful of the companies highlighted in the Fierce article have participated in the company presentation opportunities afforded through BIO’s business development meetings. Immune Design presented at the 2013 BIF Investor Forum and the 2014 CEO & Investor Conference while Syndax Pharmaceuticals is scheduled to present at this year’s BIO Investor Forum.